IGAS

This page shows the latest IGAS news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Karuna raises $42m for novel CNS approach, Chen exits Roche, Orchard gains GSK board member

Immunoglobulins, also known as antibodies, comprise a family of proteins that occur in five major forms: IgM, IgD, IgG, IgE and IgA.

Morning brief: Sanofi's shaky start, pharma begins talks with UK government and more

This is the second breakthrough therapy drug designation for OMS721, which gained the status last year for treatment of Immunoglobulin A (IgA) nephropathy, in which pivotal phase III trials recently begun.
Rigel and Ultragenyx claim approvals for rare drugs

Rigel is also developing it for additional indications, including autoimmune haemolytic anaemia and IgA nephropathy.
Rigel shaken after fostamatinib misses phase III trial target

Estimates for peak sales are in the $300m-400m range. Fostamatinib is also in phase II trials for two other rare diseases - autoimmune haemolytic anaemia and IgA nephropathy.
Retrophin rockets away as rare disease trial hits targets

He added that after taking on the drug a decision had to be taken on developing it for FSG or another rare kidney disease called IgA nephropathy, as there was only
Firms at fault in fatal clinical trial, says French government

The IGAS launched the probe in January in the wake of the death of Guillaume Molinet, which occurred in a first-in-man trial at Biotrial's phase I trial facility ... It also vehemently contests the findings of the IGAS report, saying it failed to take

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Hayward Medical Communications launch a new, eye-opening journal

Hayward is particularly pleased that the journal features regular columns from the International Glaucoma Association (IGA) and the Royal National Institute of Blind People (RNIB). .

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...: EXCELLENT DAY RATES AVAILABLE

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Manager - Immunology, Therapeutic Area Communications & Publ...: Competitive Salary Offered

Senior Account Executive with progression to Account Manager, Me...: Excellent package

Senior Developer with management potential, Healthcare Brand Com...: circa £50K

Add my company

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

AstraZeneca’s oncology renaissance: Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis: Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls: ‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...